Testosterone Replacement Therapy: The Definitive Guide for 2026

What Is Testosterone Replacement Therapy?

Testosterone is the primary androgen in males, responsible for muscle mass, bone density, red blood cell production, fat distribution, libido, and cognitive function. The hypothalamic-pituitary-gonadal (HPG) axis regulates its production: the hypothalamus releases gonadotropin-releasing hormone (GnRH), which signals the pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the Leydig cells of the testes to produce testosterone.

Hypogonadism occurs when this axis fails at any level. Primary hypogonadism (testicular failure) presents with low testosterone, elevated LH and FSH. Secondary hypogonadism (pituitary or hypothalamic dysfunction) shows low testosterone with low or inappropriately normal gonadotropins. TRT directly replaces the deficit with exogenous testosterone, restoring serum levels to the physiological range of 450–1,000 ng/dL.

Modern TRT goes beyond monotherapy. Clinicians now routinely address estrogen conversion via aromatase inhibitors, maintain fertility with HCG or gonadorelin, protect against hair loss with finasteride or dutasteride, and manage sexual health with PDE5 inhibitors. The goal is not just a number on a lab report but the resolution of symptoms: improved energy, restored libido, better body composition, sharper cognition, and enhanced mood stability.

TRT Compound Library

Testosterone Esters

Fertility Preservation

Estrogen Management

Sexual Health & Hair

Hormone Precursors

Common Protocols

Standard TRT dosing for testosterone cypionate or enanthate is 100–200 mg per week, split into two or three subcutaneous or intramuscular injections. Splitting the dose (e.g., 70 mg every 3.5 days instead of 140 mg once weekly) reduces peak-trough fluctuations, minimizes estrogen conversion, and improves mood stability. Subcutaneous injection in the abdominal or deltoid fat pad has become increasingly popular due to slower absorption, more stable levels, and easier self-administration compared to intramuscular gluteal injections.

Testosterone cream (typically compounded at 200 mg/mL) is applied to the scrotum or inner arm at 1–2 clicks (10–20 mg) twice daily. Scrotal application produces higher DHT conversion, which some patients prefer for libido and mood. Transdermal routes avoid first-pass liver metabolism and produce minimal erythrocytosis compared to injections.

HCG at 250–500 IU two to three times per week alongside TRT preserves intratesticular testosterone, spermatogenesis, and testicular volume. Gonadorelin at 100–400 mcg subcutaneously every other day serves as an alternative following the FDA’s reclassification of HCG. Anastrozole at 0.25–0.5 mg twice weekly is used only when estradiol exceeds 40–50 pg/mL with symptoms; routine AI use without elevated estrogen is no longer considered best practice.

Low-dose daily tadalafil (2.5–5 mg) is commonly prescribed alongside TRT for its dual benefits: improved erectile function and enhanced lower urinary tract symptoms. Finasteride at 1 mg daily or 3 times per week protects against androgenic alopecia. DHEA at 25–50 mg daily and pregnenolone at 50–100 mg daily help maintain downstream neurosteroid and adrenal hormone levels that may be suppressed by exogenous testosterone.

Who Should Consider TRT?

Men with two separate morning total testosterone measurements below 300 ng/dL combined with clinical symptoms—fatigue, reduced libido, erectile dysfunction, depression, loss of muscle mass, increased body fat, or brain fog—are candidates for TRT. The Endocrine Society guidelines recommend testing between 7:00 and 10:00 AM when testosterone peaks. Free testosterone, SHBG, LH, FSH, estradiol, and prolactin should also be evaluated to determine the underlying cause.

TRT is contraindicated in men actively trying to conceive (without concomitant HCG/gonadorelin), those with untreated severe obstructive sleep apnea, polycythemia vera, or PSA elevation suggesting undiagnosed prostate pathology. Men with a history of hormone-sensitive cancers should be evaluated by an oncologist before starting therapy. Younger men (under 35) should exhaust lifestyle optimization and consider Clomiphene or Enclomiphene monotherapy before committing to exogenous testosterone.

Monitoring & Safety

Bloodwork should be drawn at baseline, 6 weeks, 12 weeks, and then every 6 months once stable. The core TRT panel includes: total testosterone, free testosterone (equilibrium dialysis preferred), estradiol (sensitive LC/MS assay), complete blood count with hematocrit, comprehensive metabolic panel, lipid panel, PSA, and LH/FSH. Hematocrit above 54% requires dose reduction, more frequent injections, therapeutic phlebotomy, or switching to a transdermal formulation.

Estradiol should be maintained at 20–40 pg/mL for most men. Symptoms of elevated estrogen include water retention, mood swings, tender nipples, and reduced libido. Symptoms of crashed estrogen (over-use of AI) include joint pain, dry skin, anxiety, and erectile dysfunction. The sensitive estradiol assay (LC/MS/MS) is essential—the standard immunoassay is unreliable in males.

Monitor cardiovascular markers including lipids, blood pressure, and hematocrit. TRT can reduce HDL by 10–15%, particularly with oral androgens. Annual DEXA scans track bone density improvements. Digital rectal exams and PSA monitoring should follow standard urological guidelines. Report any chest pain, severe headaches, visual disturbances, or significant leg swelling to your physician immediately.

Frequently Asked Questions

Does TRT cause infertility?

Exogenous testosterone suppresses the HPG axis, dramatically reducing intratesticular testosterone and, consequently, sperm production. This effect is reversible in most men within 6–12 months of discontinuation, but recovery is not guaranteed. HCG (250–500 IU 2–3x/week) or gonadorelin used alongside TRT can maintain spermatogenesis. Men planning to conceive should discuss fertility preservation strategies with their physician before starting.

Is TRT safe long-term?

Long-term data from the TRAVERSE trial (2023) demonstrated no increased risk of major adverse cardiovascular events in men on TRT compared to placebo over a median follow-up of 33 months. The key to safety is proper monitoring: regular bloodwork, hematocrit management, cardiovascular screening, and prostate health surveillance. Most adverse effects (erythrocytosis, acne, sleep disturbance) are dose-dependent and manageable with protocol adjustments.

How quickly will I feel the effects?

Libido and energy improvements often appear within 3–6 weeks. Mood and cognitive benefits typically manifest by 6–12 weeks. Body composition changes (increased lean mass, reduced fat) require 12–16 weeks of consistent therapy combined with resistance training and adequate protein intake. Full optimization of bone density takes 12–24 months.

Can I stop TRT once I start?

Yes, but testosterone levels will return to pre-treatment baseline (or potentially lower temporarily). Post-cycle therapy (PCT) with Clomiphene (25–50 mg daily) or Enclomiphene (12.5–25 mg daily) for 4–8 weeks can accelerate recovery of the HPG axis. The longer you have been on TRT and the older you are, the slower the recovery. Some men choose to remain on TRT indefinitely, treating it like any other chronic medication for a chronic condition.